Cornerstone Diagnostics INC

Cornerstone Diagnostics INC was paid $8.94M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 44% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#12 of 73

Median peer was paid$95K

This provider vs. median94×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	79,960	$1.54M
2019	48,228	$1.40M
2020	32,335	$918K
2021	32,022	$1.26M
2022	31,065	$1.22M
2023	45,630	$1.43M
2024incomplete	28,769	$1.17M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	44%	118,442	74,135	$3.96M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	36%	61,512	32,454	$3.19M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	16%	82,802	52,827	$1.44M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.6%	3,069	2,601	$140K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	2,392	1,984	$34K
87522	Neg quan hep c or qual rna	<1%	807	578	$14K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	1,386	991	$13K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,240	942	$13K
80050	General health panel	<1%	494	415	$11K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	642	481	$9K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	642	480	$9K
82607		<1%	1,211	896	$7K

49 more codes

80061	Lipid panel	<1%	1,231	$7K
84443	Thyroid stimulating hormone (TSH)	<1%	987	$6K
80053	Comprehensive metabolic panel	<1%	1,356	$5K
80074		<1%	470	$5K
80372		<1%	460	$5K
86803		<1%	778	$4K
83992		<1%	465	$4K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,400	$4K
36415	Collection of venous blood by venipuncture	<1%	1,632	$4K
86704		<1%	671	$4K
86706		<1%	738	$3K
82746		<1%	575	$3K
86708		<1%	493	$3K
83036	Hemoglobin; glycosylated (A1C)	<1%	949	$3K
87340		<1%	596	$3K
80355		<1%	481	$2K
80361		<1%	490	$2K
80365		<1%	489	$2K
80373		<1%	486	$2K
80354		<1%	486	$2K
80356		<1%	490	$2K
80346		<1%	473	$2K
80348		<1%	478	$2K
80368		<1%	472	$2K
80358		<1%	486	$2K
80349		<1%	467	$2K
80359		<1%	461	$2K
80353		<1%	461	$2K
80345		<1%	461	$2K
80360		<1%	461	$2K
80369		<1%	463	$2K
80366		<1%	463	$2K
81025		<1%	532	$2K
80324		<1%	456	$2K
84403		<1%	145	$2K
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	58	$1K
84481		<1%	131	$1K
86592		<1%	523	$801.50
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	37	$624.24
G0499	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result	<1%	41	$522.80
86709		<1%	123	$518.30
86780		<1%	87	$476.36
84439		<1%	96	$453.04
86705		<1%	98	$427.53
80048	Basic metabolic panel (calcium, ionized)	<1%	76	$201.28
82728		<1%	19	$106.75
84702		<1%	23	$97.86
85027		<1%	35	$63.23
80076		<1%	21	$53.31

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOUCHILLON, WILLIAM (CEO)

Same official

Other billing entities under BOUCHILLON, WILLIAM

Full network →

Provider	Location	Paid
Crescent City Surgical Centre Diagnostics, LLC	Metairie, LA	$22K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.